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Purpose/objective: Whole ‘‘conventional’’ pelvic irradiation (up to 45–50 Gy) following hysterectomy is
associated with a high rate of adverse gastro-intestinal (GI) adverse events, of which around 60% corre-
spond to acute grade 2 toxicity. The phase II RTCMIENDOMETRE trial was designed to test the hypothesis
that IMRT could reduce the incidence of grade 2 or more acute GI toxicity to less than 30% in patients
irradiated post-operatively for an endometrial cancer.
Materials/methods: Patients with post-operative stage Ib G3, Ic or II endometrial carcinomas with no his-
tory of chronic inﬂammatory bowel disease were eligible. Guidelines for volume delineation and dose
prescription were detailed in the protocol. The investigators were advised to use a web-based atlas devel-
oped for the RTOG 0418 study. The dose of the vaginal and nodal PTV was 45 Gy in 25 fractions. To assess
the ability of the participating centres to comply with the protocol guidelines, they were requested to
complete a dummy run procedure before inclusion of their 1st patient. GI and genito-urinary (GU) tox-
icity were graded according to the CTCAE V 3.0 classiﬁcation and were prospectively recorded every week
during irradiation, as well as at time of brachytherapy insertions and during the follow-up visit at week
15 (W15). Special attention was given to note any changes to the grade of adverse events between W5
and W15.
Results: From May 2008 to April 2010, 49 patients from 6 centres were recruited for the trial. One patient
could not be treated, one patient died of vascular stroke at W3 without toxicity, and 1 patient refused to
be followed-up after treatment. Thus, 46 cases were available for analysis at W15. The distribution by
stage was as follows: Ib 16.3%, Ic 64.2%, II 20.4%. Thirty six patients (75%) received an additional vaginal
vault boost of 6–10 Gy delivered by HDR brachytherapy in 1 or 2 fractions. Among the 47 patients who
completed IMRT, 27% (95% CI 14.5–39.7%) developed at least 1 GI grade 2 adverse event (diarrhoea in 92%
of cases), which mainly occurred at W4 and W5. No event corresponding to grade 3 or above was
recorded. At W15, the number of patients complaining about GI events was low: 5 patients complained
about persistent grade 1 diarrhoea, and 4 patients complained about haemorrhoids. Nineteen percent
(95% CI 8.9–32.6%) of patients experienced grade 2 cystitis or urinary frequency which had disappeared
by W15.
Conclusion: In accordance with our hypothesis, post-operative IMRT resulted in a low rate (less than 30%)
of acute GI grade 2 toxicity, in patients with endometrial carcinomas. At W15, no patient demonstrated a
grade 2 adverse event, and the prevalence of remaining grade 1 events was less than 20%.
 2014 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 111 (2014) 138–143
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/3.0/).Adjuvant pelvic radiotherapy following hysterectomy exposes
patients to the potential side effects of both surgery and radiation.
These side effects notably include gastro-intestinal (GI) toxicity. In
40–60 % of cases, whole ‘‘conventional’’ pelvic irradiation of up to
45–50 Gy results in acute GI grade 2 side effects, and in 26% of
cases, this procedure is associated with late GI toxicity. Severe
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enced an acute adverse event (grade 2 or higher) [1–4]. Over the
past decade there has been interest in the use of intensity-modu-
lated radiation therapy (IMRT) for patients receiving adjuvant
post-operative radiation for cervical or endometrial carcinomas.
IMRT minimises the dose of radiation to healthy tissue and thereby
theoretically reduces the risk of acute and long-term toxicity. Pre-
clinical studies of post-operative IMRT in endometrial cancer dem-
onstrate that the volume of the bowel that receives the prescribed
dose may be reduced by 30–50%; therefore, one could expect that
the occurrence of GI toxicity is lower for IMRT than for conven-
tional methods [5–8]. Most reports in the literature support this
hypothesis, and promising preliminary results from single centre
studies have translated into clinical improvements with lower
rates of both acute and late toxicity for IMRT than for conventional
methods [9–12]. However, there have been few controlled pro-
spective multicentre studies [13].
RTCMIENDOMETRE is a prospective French phase II multicentre
trial which was designed in 2007 to test the hypothesis that among
cases of post-operative stage I or II endometrial cancer treated by
IMRT, the incidence of acute grade 2 GI toxicity was less than 30%.Materials and methods
Inclusion and exclusion criteria
Patients who were older than 18 years and had a post-operative
stage Ib grade 3, or stage Ic or II grade 1–3 endometrioid carcinoma
(1994 FIGO classiﬁcation) without any history of GI and/or genito-
urinary (GU) disorders were eligible for inclusion. The patients
underwent a total hysterectomy with bilateral oophorectomy by
laparotomy or laparoscopy. Bilateral ilio-obturator lymphadenec-
tomy was recommended. Patients with histological subtype 2 car-
cinomas or with a history of chronic inﬂammatory bowel disease
were excluded. The other exclusion criteria were inadequate sur-
gery, previous pelvic irradiation, another progressive cancer, and
a contraindication to injection of contrast agent during a planning
CT scan.Table 1
Dose constraints to organs at risk.
Rectum, sigmoïd Maximal dose 45 Gy
Median dose <40 Gy
V40 Gy 640%
Bladder Maximal dose 45 Gy
Median dose <40 Gy
V40 Gy 640%
Femoral heads V50 Gy <10%
Peritoneal cavity V30 Gy 6500 cc or V40 Gy 6300 ccContouring and dose prescription
Patients were positioned supine on a knee wedge and foot rest
or with another type of immobilisation device according to the
standard protocol at each centre. Two consecutive series of CT-
images (3 mm slice thickness) were acquired: one series was car-
ried out without the injection of intravenous contrast agent for
dose calculation (reference series), and a second series (using the
same DICOM coordinates) was carried out for contouring. The low-
er limit of the scanned area was set to 2 cm below the lower limit
of the lesser trochanter and the upper limit was in the L2–L3 inter-
space. Patients were treated with a full bladder: they were asked to
empty their bladder 30 min before CT and each treatment session,
and then to drink 330 cm3 –volumes of water within the following
15 min. No measure was taken to control rectum ﬁlling because
variation of rectal volume is usually small [14]. However, if the rec-
tum was abnormally full or distended, CTs were repeated within
several days and were carried out following enema if necessary.
As recommended in the Radiation Therapy Oncology Group
(RTOG) 0418 trial, the RTOG atlas was used to help delineate nodal
target volumes [15]. The vaginal volume was given by the vaginal
vault and the upper third of the remaining length of the vagina. The
clinical target volume (CTV) included the vaginal volume expand-
ing laterally and caudally by 1 cm and cranially by 2 cm, and the
internal, external, and common iliac lymph nodes. The planning
target volume (PTV) was generated from the CTV by adding
7 mm margins. The outer contours of the bladder, rectum, and sig-moid were drawn. The dummy run procedure demonstrated that
the outlining of bowel loops was unreliable and we opted to use
the content of the peritoneal cavity, excluding the CTV, as a surro-
gate of the bowel [16]. The bladder was drawn on each slice, from
the base to the dome, the rectum was drawn from the ano-rectal
junction to the recto-sigmoid junction, and the sigmoid was drawn
from the upper limit of the rectum to the last slide where it was
easily seen. The peritoneal cavity was contoured 2 cm above the
PTV. Femoral heads were delineated from the top of the hip joint
to the lower limit of the lesser trochanter.
The prescribed dose was 45 Gy in fractions of 1.8 Gy, 1 fraction
per day, 5 days per week. Dose distribution was considered as opti-
mal if 100% of the CTV received 45 Gy and if PTV dose homogeneity
was within 90% and 115% of the prescribed dose (V40.5 Gy P95%
and V52 Gy 65%). Recommended dose constraints to organs at risk
(OAR) are presented in Table 1.Treatment veriﬁcation
The alignment of the isocenter had to be checked by 2D orthog-
onal or by 3D images (CBCT or MVCT) according to the veriﬁcation
and correction procedure of each centre. If an online procedure was
used, physicists were advised to take into account the dose deliv-
ered by imaging, in the calculation of the dose distribution.Quality assurance procedure
Participating centres were requested to participate in a dummy
run procedure prior to the inclusion of their ﬁrst patient, to assess
their ability to comply with the protocol guidelines. Three out of
seven participating centres complied with protocol requirements
for CTV delineation without correction. In three centres, the length
of the delineated vagina was too long (2/3 instead of 1/3), and in
one centre the delineation of the iliac nodes was extended beyond
the iliac bifurcation. All four centres were asked to correct these
shortcomings. Delineation of the bladder and rectum was highly
consistent across centres (mean Kappa index was 0.94 for the blad-
der and 0.78 for the rectum). All centres delineated the sigmoid
with good agreement over most of its volume but its lower and
upper anatomical limits varied across centres, thus affecting the
Kappa index value (mean Kappa index 0.54). This was acceptable
however, because (i) the rectum and the sigmoid are contiguous
and are thought to tolerate radiation equally, and (ii), the true
upper limit of sigmoid was included in the bowel volume. There
was very poor agreement in the delineation of the small intestine
whereas the peritoneal cavity was delineated consistently across
centres (mean Kappa index 0.91), and was deﬁnitely chosen as a
surrogate for the bowel in the trial. This dummy run procedure also
revealed that all centres had no difﬁculty in complying with PTV,
rectum, and bladder dose constraints (mean V40.5 Gy PTV: 97.8%
(range 95–100%); mean V40 Gy rectum 24.7% (range 14–37%);
mean 40 Gy bladder: 31% (range 23–40%). Only half of the centres
achieved V40 Gy 640% for the sigmoid (mean 43.5%), and the con-
straint of V30 Gy 6300 cc to the peritoneal cavity was clearly too
140 Phase II RTCMIENDOMETRE trialstringent; therefore, the more realistic constraints of V30 Gy
6500 cc or V40 Gy 6300 cc were used in the trial.
On site data monitoring was performed: each centre was visited
three times.Ethics
The protocol was reviewed and approved by the ethics commit-
tee and by the French National Agency of Medicine and Health
Products Safety (ANSM).Endpoints
Primary endpoint
The primary endpoint was the incidence of acute GI toxicity
classiﬁed as grade 2 or higher according to the CTCAE 3.0, observed
during irradiation or during the 10 following weeks (i.e. within
90 days of treatment).
Secondary endpoints
The assessment of acute GU toxicity and the evaluation of any
other type of toxicity were considered as secondary endpoints.Evaluation of toxicity
Acute side effects were recorded from week 1 to 5 during the
weekly examination, at time of each brachytherapy insertion, and
then during the closing visit at week 15. Acute side effects were
scored according to the Common Terminology Criteria for Adverse
Events v3.0 (CTCAE-3.0), and any decline or increase in the severity
of the side effects since the end of the irradiation was noted. Symp-
toms that are not spontaneously reported by patients tend to be un-
der-reported, especially if the symptoms have resolved by the time
of examination, and physician directed investigations may intro-
duce bias; therefore, we postulated that the description of symp-
toms would be more complete if patients were actively involved
in recording their symptoms, in addition to undergoing a weekly
objective assessment by a physician. We provided a simple note-
book that enabled patients to make a daily record of their various
symptoms in a number of domains. To construct this patient note-
book, we extracted from the CTCAE v3.0 the 14 adverse eventsmost
commonly reported by patients in daily practice: eight gastrointes-
tinal events (Pain, nausea, vomiting, diarrhoea, bleeding, mucositis,
incontinence, and haemorrhoids), ﬁve genitourinary events (uri-
nary frequency, spasms, bleeding, incontinence, vaginal bleeding),
and one skin complaint. Each event was then converted into a sim-
ple question that the patient could easily understand and that gave
an answer that could be transposed directly into a CTCAE v3.0 grade
for a given side-effect. For example in answer to the question ‘‘How
many daily bowelmovements did you have?’’ patients had to report
a number and the grade was scored according to that number:
grade 1 (less than 4 over baseline), grade 2 (4–6), or grade 3 (more
then 6). In answer to the question ‘‘Have you noticed an increase in
daily urinary frequency?’’, the patient indicated: 0 if No; 1 if Yes, up
to twice as frequent (or excessive urination at night); 2 if Yes, more
than twice as frequent but less than hourly; 3 if Yes, more than once
per hour.
For the sake of clarity, the gastro-intestinal complaints were re-
corded on a different page from urinary and skin complaints. There
was a space for comments and for reporting other symptoms at the
bottom of each page. At each clinical examination, the notebook
was shown to a physician who converted the patient’s daily re-
sponse into a grade for each symptom. Side-effects, such as vaginal
mucositis were also assessed during the clinical examination. Only
the highest grade for each side-effect observed during a given week
was reported in the patient’s ﬁle.Statistical methods
Descriptive statistics were computed using SAS software ver-
sion 9.2 and R version 12.2. Two-sided 95% conﬁdence intervals
were calculated by the Wald method, or by the binomial exact
method if the sample was small.Results
Patients
From May 2008 to March 2010, 49 patients were entered into
the trial by 6 institutions. One patient had a bilateral hip replace-
ment that induced diffuse artefacts in CT and was excluded be-
cause volumes of interest could not be deﬁned. This patient only
received brachytherapy. Another patient died of a vascular stroke
during the third week of treatment, without evidence of toxicity.
At the end of external irradiation (week 5), data from 47 patients
were fully available for analysis. One patient subsequently refused
to be followed up. At week 15 the analysis included the 46 remain-
ing patients. Patient characteristics are presented in Table 2. Mean
patient age was 66 years [range: 57–75 years]. All patients under-
went surgery according to the protocol guidelines. Bilateral ilio-
obturator lymphadenectomy was performed in 96% of cases.
According to the 1994 FIGO classiﬁcation, 8 patients (16.3 %) were
stage Ib, 31 patients were stage Ic (36.2%) and 10 patients were
stage II (20.4%). Thirty patients (62.5%) had a WHO histopronostic
grade of 1 or 2 and all patients with stage Ib were grade 3.Treatment characteristics
‘Step and shoot’ or ‘slidingwindow’ techniqueswere used in two
thirds (69%) of the 48 patients who received IMRT, and helical
Tomotherapy was used in 31% of cases. The dose distribution of
CTV and PTV in each patient strictly complied with the protocol
constraints: on average, the volume of PTV receiving at least 90%
of the prescribed dose (V40.5 Gy)was 99.1% and no patient received
more than 52 Gy. The mean and median dose values delivered to
the CTV and to OAR are reported in Table 3. Thirty six patients re-
ceived an additional vaginal vault boost delivered with HDR brach-
ytherapy. The CTV was limited to the upper third of the vagina
(mean treated length = 25 mm). Twenty three patients received
6 Gy in one fraction and 13 patients received 10 Gy in two fractions
at week 7 or week 8. The prescribed dose corresponded to the dose
at 5 mm depth from the mucosa–applicator interface.Gastro-intestinal toxicity
Fourteen patients presented with minor morbidity (abdominal
pain and/or haemorrhoids) at baseline. Among the 47 patients
who completed IMRT, 13 of them (27.1%) (95% CI 14.5–39.7%)
developed at least one GI grade 2 adverse event which mainly oc-
curred at week 4 or week 5 (Fig. 1). No adverse event classiﬁed as
grade 3 or above was observed. Of the 13 patients, nine had diar-
rhoea only, one had diarrhoea and enteritis, one had diarrhoea
and incontinence, one had diarrhoea, enteritis, and proctitis, and
the remaining patient complained of nausea at the time of the ﬁrst
brachytherapy insertion. Although the relationship between nau-
sea and the treatment was not evident, we ﬁnally considered that
they could be related, because the patient presented grade 1 diar-
rhoea at week 4 and week 5. Among the 36 patients who received
brachytherapy, all of the 8 patients who demonstrated grade 2
diarrhoea at time of insertion had experienced grade 2 diarrhoea
during the previous weeks. This suggests that brachytherapy did
not increase the severity of diarrhoea induced by IMRT.
Table 2
Patient, surgery, and tumour characteristics (n = 49).
Characteristics
Age (year)
(Mean ± SD) 65.5 ± 8.9
Median [Q1; Q3] 66 [60; 72]
BMI
(Mean ± SD) 27.3 ± 6.4
Median [Q1; Q3] 26.8 [23.1; 30.1]
WHO performance status n (%) 0 39 (79.6)
1 9 (18.4)
2 1 (2.0)
Surgical procedure n (%) 1-Abdominal extrafacial hysterectomy + BSO 27 (55.1)
2-Laparoscopic-assisted vaginal hysterectomy + BSO 22 (44.9)
3-Complete lymph node dissection 47 (95.9)
Tumour stage and grade n (%) IB grade 3 8 (16.3)
IC grade 1 10 (20.4)
IC grade 2 15 (30.6)
IC grade 3 6 (12.2)
II grade 1 5 (10.2)
II grade 2 4 (8.0)
II grade 3 1 (2.3)
BSO = bilateral salpingo-oophorectomy, SD = standard deviation, Q = quartile.
Table 3
Mean and median doses delivered to the CTV and organs at risk (n = 48 patients).
Volumes Maximum dose (Gy) Mean dose (Gy) Median dose (Gy)
CTV 48.2 ± 2.1 45.8 ± 1.2 45.3 ± 0.7
Rectum 46.3 ± 1.6 33.2 ± 5 34.3 ± 5.1
Sigmoïd 46.7 ± 2.6 36 ± 4.1 37.5 ± 4.9
Bowel 48.4 ± 1.8 19.7 ± 7.1 19.1 ± 6.7
Bladder 46.8 ± 1.7 32.8 ± 3.4 31.8 ± 4.9
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from grade 1 diarrhoea and 4 patients were suffering from grade
1 haemorrhoids.Genito-Urinary toxicity
Acute urinary toxicity was less frequent than acute GI toxicity.
Indeed, considering the whole population and all adverse events,
whatever the grade, 39.5% of cases suffered from acute urinary tox-5100G2
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Fig. 1. Crude incidence of GI acute gricity whereas 85% of cases suffered from acute GI toxicity. Nine pa-
tients (19%) (95% CI 8.9–32.6%) experienced a grade 2 urinary side
effect: cystitis in 3 patients, and increase of urinary frequency in 6
patients.
Gynaecological examination revealed a grade 1 vaginal ery-
thema in most patients at the end of irradiation, but only 3 patients
complained spontaneously in relation to a mild vaginal discharge.
Vaginal dryness and vulva pruritus were mentioned by 6 patients.Other toxicity
The combination of lymphadenectomy and post-operative irra-
diation led to mild lymphoedema in the legs of 6 patients.Discussion
IMRT is considered to be a major advance in radiotherapy be-
cause this technique limits the dose of radiation to normal tissues02886
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142 Phase II RTCMIENDOMETRE trialwhile potentially delivering a high dose to gross tumour volume
(GTV) and/or CTV at many tumour locations. The main motive
for the introduction of post-operative pelvic irradiation in clinical
practice is that this technique may minimise gastrointestinal tox-
icity. The PORTEC 2 trial investigated the use of brachytherapy in
patients with endometrial cancer of high-intermediate risk [17].
In most cases of patients with stage I intermediate risk, brachy-
therapy achieved local tumour control rates equivalent to those
obtained with pelvic irradiation but with less toxicity [17]. Brach-
ytherapy can be now used as the sole post-operative adjuvant
treatment. However, an increasing number of patients with poor
prognostic factors are still amenable to the administration of
post-operative external beam radiotherapy, whose toxicity could
be increased by combining it with chemotherapy. This particular
aspect is under investigation in the PORTEC 3 trial.
The RTCMIENDOMETRE phase II multi-institutional trial is the
second trial that shows the beneﬁts of irradiation by an intensity
modulated technique in patients treated post-operatively for an
endometrial carcinoma. Indeed, it is the second trial to show that
this technique is associated with a rate of less than 30% of acute
GI toxicity (grade 2 or higher) in these patients.
The ﬁrst phase II trial of post-operative IMRT in gynaecological
malignancies (involving cervical and endometrial carcinomas) was
launched in 2006 by the Radiation Therapy Oncology Group
(RTOG0418 trial). The primary objective of this trial was to deter-
mine the feasibility of post-operative IMRT in a multi-institutional
setting and to establish whether the promising clinical results ob-
served in single-institution studies could be reproduced. The re-
sults of this trial involving acute GI toxicity in patients with
endometrial carcinomas have been published [13], and may be
considered as the most relevant reference for the discussion of
the ﬁndings of our RTCMIENDOMETRE trial. The two target popu-
lations should be comparable because both trials included around
50 patients with endometrioid carcinomas who received pelvic
post-operative IMRT without concurrent administration of chemo-
therapy. Thirty six patients in the French trial received an addi-
tional vaginal boost after IMRT that was delivered by HDR
brachytherapy; however, the weekly recording of toxicity was
carefully planned to be able to discriminate the inﬂuence of each
treatment on the side effects. Surgery mainly consisted in total
hysterectomy or bilateral salpingo-oophorectomy. A similar per-
centage of patients from North America (98%) and France (96%)
underwent complete lymph node dissection. Thus, the risk of com-
plications related to the extent of surgery should be similar in the
two groups. Treatment-related GI bowel adverse events (grade 2 or
higher) occurring within 90 days of treatment were carefully as-
sessed using the CTCAE 3.0. Radiation-induced toxicity is usually
evaluated by a physician during a weekly examination. However,
symptoms of toxicity may be under-evaluated or omitted in the
absence of spontaneous complaints by the patient; therefore, we
took steps to ensure that all side effects were thoroughly docu-
mented in the French trial. Patient self-assessments have been
commonly and successfully used to determine pain, quality of life,
and in some studies, side effects [18–20]. We thus decided to ask
patients to make a daily record of all signs and symptoms during
radiation therapy for discussion with their physician at their
weekly consultation, to reﬁne the grading of GI adverse events.
Fifty eight patients were recruited by 25 institutions in the
RTOG0418 trial and 43 were eligible for analysis. In the RTCMIEN-
DOMETRE trial, we enrolled 49 patients from 6 centres and 47 pa-
tients could be evaluated. The incidence of GI acute toxicity (grade
2 or higher) was 28% in the RTOG0418 trial and 27% in the RTCMI-
ENDOMETRE trial. Not surprisingly, the nature and timing of GI
toxicity in these two trials were similar: most patients complained
of diarrhoea and/or enteritis and/or proctitis, which were mainly
diagnosed during the last days of irradiation.However, the conclusions of our study must be considered
within the context of its limitations, especially regarding the major
issues of CTV deﬁnition and organ motion [21]. The accuracy and
reproducibility of CTV and OAR delineation are of paramount
importance in IMRT, because IMRT produces sharp dose gradients.
A variation of just a few millimetres can have a considerable effect
on dose distribution and outcome; therefore, emphasis was placed
on quality assurance in the RTOG trial, which included a centra-
lised review of each case (contouring and planning). In the RTOG
trial, the volume deﬁnition of bowel and the dosimetric constraints
for bowel, rectum, bladder, and femoral heads required some revi-
sion. Nonetheless, fewer than 5 patients had unacceptable dose
variation in the PTV; thus implementation of the technique with
the use of a detailed protocol and centralised quality assurance
was considered feasible across multiple institutions. In the French
trial we could only plan a dummy run procedure to assess the abil-
ity of the participating centres to comply with the protocol guide-
lines. This dummy run procedure revealed 4 centres that did not
comply with the protocol recommendations regarding the delinea-
tion of the CTV and these centres were asked to correct these short-
comings. On the other hand, the delineation of organs at risk was
reasonably consistent. The lack of central review for all cases
may limit the validity of our results, as we are not able to say that
all patients were treated without any major deviations to protocol.
In the mid-2000s, IMRT was not widely used to treat gynaeco-
logical cancers and there were very few guidelines for the imple-
mentation of this technique in this setting. For this reason, we
also recommended the use of the RTOG atlas, which is posted on
the RTOG website, to improve the reproducibility of the delinea-
tion of nodal CTV [15]. Conversely, we determined vaginal CTV
according to our own guidelines used in 3DRT. We did not recom-
mend the construction of an internal target volume (ITV) according
to bladder ﬁlling, because we suspected that this approach would
not provide an accurate depiction of the amplitude of the CTV mo-
tion in patients that were asked to empty their bladder and then
drink before each treatment session. It is clear that this resulted
in a small target volume in the anterior–posterior axis that could
have limited the exposure of healthy tissue to radiation, with the
inherent risk that vaginal vault received too small a dose. However,
in our study this risk may have been counterbalanced by the wide
use of an additional vaginal vault brachytherapy boost. Seven years
later, the signiﬁcant and regular motion of the target area and of
organs at risk with respect to the bone landmarks remains one of
the major issues for the successful implementation of IMRT. Rou-
tine bladder ﬁlling and rectal emptying instructions can be helpful,
but do not always result in a reproducible assessment of ITV. Even
with the construction of a reliable ITV, interfraction motion (mo-
tion between treatment sessions) is a signiﬁcant problem [22].
Wagner et al. also pointed out that treatment delivery can be fur-
ther complicated by the fact that the vaginal cuff and surrounding
tissues are mobile relative to the pelvis, whereas the pelvic lymph
nodes that are also part of the target are relatively ﬁxed [21]. This
means that the use of IMRT must be coupled with 3D based image
guided radiotherapy protocols (IGRT), either with or without ﬁdu-
cial markers, to account more accurately for interfraction motion.
The review of our dummy run demonstrated that PTV compli-
ance criteria, which were similar to those used in the RTOG trial,
were met in all patients. However, we were unable to ﬁnd any cor-
relation between the observed toxicity and dose parameters, due
perhaps to two weak points in our study: (i) the lack of central re-
view of each case, and (ii) because the fact that we only recorded
minimal, mean, median, and maximum doses to organs at risk in
the patient ﬁle. In the RTOG trial, doses received by the bladder ex-
ceeded the recommended constraints in 68% of the treatment
plans and doses received by the rectum exceeded the recom-
mended constraints in 76% of treatment plans. However, GI acute
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itoneal cavity than that of the rectum. A wide range of dose con-
straints for the bowel are found in the literature, including
V15 Gy <100–150 cc, V30 Gy <300–500 cc, and V50 Gy <35–
100 cc. Indeed, there is currently no standard threshold for the vol-
ume or percentage of bowel that can be irradiated, because no par-
ticular value has been convincingly shown to be associated with
higher likelihood of acute toxicity [23–26]. In the framework of
our dummy run procedure we proposed V30 Gy 6300 cc as a dose
constraint for the bowel. However, this ﬁgure was clearly too strin-
gent and V30 Gy 6500 cc or V40 Gy 6300 cc were used in the trial.
The mean dose to the bowel was 19 Gy in our population. The
investigators of the RTOG trial used V40 Gy 630% and observed
that dose to the bowel exceeded acceptable variation in 17% of pa-
tients. These two studies underline the need for detailed guidelines
for the delineation of the bowel in patients treated with pelvic
IMRT, in addition to universally accepted dose constraints for this
organ, especially for the treatment of a CTV that includes pelvic
lymph nodes.
In the RTCMIENDOMETRE trial, we only focused on acute toxic-
ity, and thus we cannot conclude anything about late toxicity or
treatment efﬁcacy. Results of the RTOG0418 trial regarding these
endpoints are pending. The inﬂuence of IMRT on survival rates of
gynaecological cancers requires further investigation in a phase
III trial. The RTOG/GOG have recently opened the phase III random-
ised Time-C trial, which compares 3DCRT and IMRT in patients
post hysterectomy.Conclusions
According to our hypothesis, the RTCMIENDOMETRE trial dem-
onstrates that among cases of post-operative endometrial cancer
treated by IMRT, the incidence of acute GI grade 2 toxicity was less
than 30%. The incidence of GU grade 2 toxicity was also lower than
20%. Despite the limitations of this trial, these ﬁndings are consis-
tent with results of the endometrial arm of the RTOG0418 trial, and
suggest that IMRT may be used in centres that are committed to
following published guidelines. Detailed deﬁnition of OAR, espe-
cially the bowel, together with reliable dose/volume constraints
and validated IGRT protocols are still needed for further reduction
of morbidity and for adequate coverage of target volume. The
ongoing phase III randomised time-C trial will contribute to clarify
the utility of the post-operative IMRT for the treatment of endome-
trial carcinoma.
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